OncLive® and the Ruesch Center for the Cure of Gastrointestinal Cancers announce recipients of the 2024 Luminary Awards in GI Cancers
09. Oktober 2024 10:00 ET
|
OncLive®
CRANBURY, N.J., Oct. 09, 2024 (GLOBE NEWSWIRE) -- OncLive, the nation’s leading multimedia resource for oncology professionals, and the Ruesch Center for the Cure of Gastrointestinal (GI) Cancers at...
OncLive® and the Ruesch Center for the Cure of Gastrointestinal Cancers Name Winners of the 2023 Luminary Awards in GI Cancers
11. Oktober 2023 10:55 ET
|
OncLive®
CRANBURY, N.J., Oct. 11, 2023 (GLOBE NEWSWIRE) -- OncLive, the nation’s leading multimedia resource for oncology professionals, and The Ruesch Center for the Cure of Gastrointestinal (GI) Cancers,...
OncLive and the Ruesch Center for the Cure of Gastrointestinal Cancers Name Winners of the 2022 Luminary Awards in Gastrointestinal Cancers
09. November 2022 09:00 ET
|
OncLive®
CRANBURY, N.J., Nov. 09, 2022 (GLOBE NEWSWIRE) -- OncLive®, the nation’s leading multimedia resource for oncology professionals, and The Ruesch Center for the Cure of Gastrointestinal (GI) Cancers,...
Rhizen Pharmaceuticals S.A. announces poster presentation of RP4010, a calcium release-activated calcium (CRAC) channel inhibitor in preclinical models of Gastrointestinal (GI) Cancers at the 2019 AACR Annual Meeting
26. März 2019 07:00 ET
|
Rhizen Pharmaceuticals SA
La Chaux-de-Fonds, Switzerland, March 26, 2019 (GLOBE NEWSWIRE) -- Rhizen Pharmaceuticals S.A. announces poster presentation of RP4010, a novel first-in-class CRAC channel inhibitor in preclinical...